Affordable Access

deepdyve-link
Publisher Website

Splicing Defect in Mitochondrial Seryl-tRNA Synthetase Gene Causes Progressive Spastic Paresis Instead of HUPRA Syndrome.

Authors
  • Linnankivi, Tarja1
  • Neupane, Nirajan2
  • Richter, Uwe2
  • Isohanni, Pirjo1, 2
  • Tyynismaa, Henna2, 3
  • 1 Department of Pediatric Neurology, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. , (Finland)
  • 2 Research Programs Unit, Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. , (Finland)
  • 3 Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland. , (Finland)
Type
Published Article
Journal
Human Mutation
Publisher
Wiley (John Wiley & Sons)
Publication Date
Sep 01, 2016
Volume
37
Issue
9
Pages
884–888
Identifiers
DOI: 10.1002/humu.23021
PMID: 27279129
Source
Medline
Keywords
License
Unknown

Abstract

Mitochondrial aminoacyl-tRNA synthetases are an important group of disease genes typically underlying either a disorder affecting an isolated tissue or a distinct syndrome. Missense mutations in the mitochondrial seryl-tRNA synthetase gene, SARS2, have been identified in HUPRA syndrome (hyperuricemia, pulmonary hypertension, renal failure in infancy, and alkalosis). We report here a homozygous splicing mutation in SARS2 in a patient with progressive spastic paresis. We show that the mutation leads to diminished levels of the synthetase in patient's fibroblasts. This has a destabilizing effect on the tRNASer(AGY) isoacceptor, but to a lesser degree than in HUPRA syndrome patients. tRNASer(UCN) is largely unaffected in both phenotypes. In conclusion, the level of tRNASer(AGY) instability may be a factor in determining tissue manifestation in patients with SARS2 mutations. This finding exemplifies the sensitivity of the nervous system to partially reduced aminoacylation, which is sufficient in other tissues to maintain respiratory chain function.

Report this publication

Statistics

Seen <100 times